Intravitreal injection of ranibizumab for treatment of macular edema caused by retinal vein occlusion

Purpose
The aim of the study was to detect the effect of intravitreal ranibizumab injection on treatment of
macular edema induced by central retinal vein occlusion (CRVO) or branch retinal vein occlusion
(BRVO) by measuring the improvement in best-corrected visual acuity (BCVA) (LogMAR) and
the reduction in central retinal thickness (CRT) measured by optical coherence tomography.
Patients and methods
In this prospective study, 50 patients with macular edema due to retinal vein occlusion (25
with CRVO and 25 with BRVO) received intravitreal injection of ranibizumab.
Results
A total of 12 weeks post-treatment, 68% of patients had an improvement in BCVA, 20% of
patients remained stable, and 12% of patients had a decrease in BCVA. In addition, 56% of
patients had decreased CRT exceeding 200 Mm and 30% of patients had decreased CRT
exceeding 100 Mm.
Conclusion
Intravitreal injection of ranibizumab resulted in significant vision improvement and a decreased
macular edema caused by CRVO or BRVO.